The FDA approved Moderna’s seasonal mRNA flu vaccine, mRNA-1010 (mFLUSIVA), marking the first mRNA flu shot cleared in the U.S. for adults aged 50–64. The decision followed a unanimous VRBPAC recommendation that benefits outweighed risks, supported by Phase 3 data (NCT05827978 and NCT06602024). In a head-to-head analysis, the vaccine was reported as 26.6% more effective than standard flu vaccination, with an overall comparable serious safety profile but higher reactogenicity reflected in more frequent mild injection-site and systemic side effects. The approval adds a new indication path for mRNA-LNP manufacturing and immunogenicity work that has largely been driven by COVID-era programs. Europe and other regions remain pending review, but the U.S. clearance strengthens the case for broader, seasonal mRNA platform deployments—especially as companies position next-generation formulations and dosing strategies for population-level vaccination campaigns.